阅读说明：本技术 含酰肼结构片段的神经氨酸酶抑制剂及其医药用途 (Neuraminidase inhibitor containing hydrazide structural fragment and medical application thereof ) 是由 田永寿 赵红倩 王矿磊 于 2020-12-01 设计创作，主要内容包括：本发明涉及药物化学领域,具体是一类含酰肼结构片段的神经氨酸酶抑制剂奥司他韦衍生物、其制备方法及其医药用途,具体涉及所述的含酰肼结构片段的神经氨酸酶抑制剂奥司他韦衍生物在制备治疗由病毒引起的感染性疾病药物中的应用。所述的的衍生物及其药学上可接受的盐或异构体如通式(I)所示,其中,R如权利要求和说明书所述。(The invention relates to the field of pharmaceutical chemistry, in particular to a neuraminidase inhibitor oseltamivir derivative containing a hydrazide structural fragmentThe preparation method and the medical application thereof, in particular to the application of the neuraminidase inhibitor oseltamivir derivative containing the hydrazide structural fragment in preparing the drugs for treating infectious diseases caused by viruses. The derivative and pharmaceutically acceptable salts or isomers thereof are shown as a general formula (I), wherein R is shown as the claims and the specification.)

1. A derivative represented by the general formula (I) and a pharmaceutically acceptable salt or isomer thereof:

wherein R independently represents a hydrogen atom, a C1-C10 alkyl group, a C3-C6 cycloalkyl group, a 5-10 membered aryl group, a 5-10 membered heterocyclic group or a 5-10 membered heteroaryl group, said heterocyclic or heteroaryl group containing 1-3 heteroatoms of N, O or S, said R being optionally substituted with one or more of the following substituents: halogen, C1-C10 alkyl, C2-C6 alkenyl, C1-C10 alkoxy and 5-10 membered aryl.

2. The derivative of claim 1 and pharmaceutically acceptable salts or isomers thereof:

wherein R independently represents a hydrogen atom, a C1-C8 alkyl group, a C3-C6 cycloalkyl group, a 5-6 membered aryl group, a 5-6 membered heterocyclyl group or a 5-6 membered heteroaryl group, which R may be substituted with one or more of the following substituents: halogen, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxy and 5-6-membered aryl.

3. The derivative of claim 1 or 2, and pharmaceutically acceptable salts or isomers thereof:

wherein R independently represents a hydrogen atom, a C1-C8 alkyl group, a C3-C6 cycloalkyl group, a phenyl group, orThe R may be substituted with one or more of the following substituents: halogen, C1-C4 alkyl,C1-C4 alkoxy, C2-C4 alkenyl.

4. A derivative according to any one of claims 1 to 3, and pharmaceutically acceptable salts or isomers thereof:

wherein R independently represents a hydrogen atom, a C1-C8 alkyl group, cyclopropane, phenyl, orThe R may be substituted with one or more of the following substituents: halogen, C1-C2 alkyl, C1-C2 alkoxy, C2-C4 alkenyl.

5. The following derivatives and pharmaceutically acceptable salts and isomers thereof:

(3R, 4R, 5S) -4-acetylamino-5- (2-methylhydrazine-1-carboxamido) -3- (pentan-3-oxy) cyclohex-1-ene-1-carboxylic acid

(3R, 4R, 5S) -4-acetylamino-3- (pentane-3-oxy) -5- (2-propylhydrazine-1-carboxamido) cyclohex-1-ene-1-carboxylic acid

(3R, 4R, 5S) -4-acetylamino-5- (2-butyrylhydrazine-1-carboxamido) -3- (pentan-3-oxy) cyclohex-1-ene-1-carboxylic acid

(3R, 4R, 5S) -4-acetylamino-5- (2-isopentylhydrazine-1-carboxamido) -3- (pentan-3-oxy) cyclohex-1-ene-1-carboxylic acid

(3R, 4R, 5S) -4-acetylamino-5- (2-heptahydrazide-1-carboxamido) -3- (pentan-3-yloxy) cyclohex-1-ene-1-carboxylic acid

(3R, 4R, 5S) -4-acetylamino-5- (2-benzylhydrazine-1-carboxamido) -3- (pentan-3-yloxy) cyclohex-1-ene-1-carboxylic acid

(3R, 4R, 5S) -4-acetylamino-3- (pentane-3-oxy) -5- (2-phenethylhydrazine-1-carboxamido) cyclohex-1-ene-1-carboxylic acid

(3R, 4R, 5S) -4-acetylamino-5- (2- (2-chlorobenzyl) hydrazine-1-carboxamido) -3- (pentan-3-yloxy) cyclohex-1-ene-1-carboxylic acid

(3R, 4R, 5S) -4-acetylamino-5- (2- (3-methoxybenzyl) hydrazine-1-carboxamido) -3- (pentan-3-yloxy) cyclohex-1-ene-1-carboxylic acid

(3R, 4R, 5S) -4-acetylamino-5- (2-cinnamoylhydrazide-1-carboxamido) -3- (pentan-3-yloxy) cyclohex-1-ene-1-carboxylic acid

(3R, 4R, 5S) -4-acetylamino-5- (2- (cyclopropylmethyl) hydrazine-1-carboxamido) -3- (pentan-3-oxy) cyclohex-1-ene-1-carboxylic acid

(3R, 4R, 5S) -4-acetylamino-3- (pentane-3-oxy) -5- (2- (tetrahydro-2H-pyran-4-yl) hydrazine-1-carboxamido) cyclohex-1-ene-1-carboxylic acid.

6. The process for the preparation of the derivatives and pharmaceutically acceptable salts thereof according to claim 1,

wherein R is as defined in claim 1.

7. A pharmaceutical composition comprising the derivative of any one of claims 1 to 5 and a pharmaceutically acceptable salt or isomer thereof as an active ingredient together with a pharmaceutically acceptable excipient.

8. Use of a derivative according to any one of claims 1 to 5, and pharmaceutically acceptable salts or isomers thereof, or a pharmaceutical composition according to claim 7, for the preparation of neuraminidase inhibitors.

9. Use of the derivative of any one of claims 1 to 5 and a pharmaceutically acceptable salt or isomer thereof or the pharmaceutical composition of claim 7 for the manufacture of a medicament for the treatment of a disease caused by an influenza virus infection.

10. Use of a derivative as claimed in any one of claims 1 to 5, and a pharmaceutically acceptable salt or isomer thereof, or a pharmaceutical composition as claimed in claim 7, for the manufacture of a medicament for the treatment of influenza.

Technical Field

The invention relates to the field of medicinal chemistry, in particular to neuraminidase inhibitor oseltamivir derivatives containing a hydrazide structural fragment, a preparation method and medical application thereof, and in particular relates to application of the neuraminidase inhibitor oseltamivir derivatives containing the hydrazide structural fragment in preparation of a medicament for treating infectious diseases caused by viruses.

Background

Influenza (influenza for short) is an acute respiratory infectious disease caused by influenza virus, wherein influenza A has strong spreading property and high morbidity and mortality, and is easy to cause pandemics or outbreaks. To date, influenza remains a disease that threatens human health.

The existing anti-influenza virus drugs mainly comprise two kinds, namely an M2 protein inhibitor and a neuraminidase inhibitor, an M2 protein inhibitor mainly comprises amantadine hydrochloride and rimantadine hydrochloride, and after the amantadine hydrochloride is orally absorbed, the amantadine hydrochloride can penetrate through a blood brain barrier to cause toxic and side reactions of a central nervous system and easily generate drug resistance.

Neuraminidase can promote host cells to release progeny viruses, so neuraminidase inhibitors can inhibit virus release and block transmission pathways, thereby playing a role in treating influenza. The structure of the active center of neuraminidase is relatively conservative, so that the neuraminidase is an ideal target for treating influenza. One such class of drugs used worldwide is zanamivir and oseltamivir phosphate. The oseltamivir phosphate is the only oral drug, can exert drug effect after being hydrolyzed into free acid (GS4071) by esterase in vivo, and active ingredients are distributed to all influenza virus infected parts including lung, trachea, nasal mucosa and middle ear, thereby greatly reducing the occurrence of complications, being one of the well-known specific drugs for resisting influenza A and avian influenza and being the anti-influenza A drug with the largest sales volume. However, some drug-resistant strains inevitably appear clinically.

Disclosure of Invention

In order to overcome the defects of the prior art, the invention provides a series of derivatives modified by hydrazide structural fragment groups of oseltamivir. Pharmacological activity test results show that the derivative has enzyme inhibition activity on neuraminidase A/Anhui/1/2005(H5N1), and part of compounds have stronger enzyme inhibition activity.

The invention provides a derivative shown as a general formula (I) and pharmaceutically acceptable salt or isomer thereof:

wherein R independently represents a hydrogen atom, a C1-C10 alkyl group, a C3-C6 cycloalkyl group, a 5-10 membered aryl group, a 5-10 membered heterocyclic group or a 5-10 membered heteroaryl group, said heterocyclic or heteroaryl group containing 1-3 heteroatoms of N, O or S, said R being optionally substituted with one or more of the following substituents: halogen, C1-C10 alkyl, C2-C6 alkenyl, C1-C10 alkoxy and 5-10 membered aryl.

The invention preferably selects the derivatives shown in the general formula (I) and the pharmaceutically acceptable salts or isomers thereof:

wherein R independently represents a hydrogen atom, a C1-C8 alkyl group, a C3-C6 cycloalkyl group, a 5-6 membered aryl group, a 5-6 membered heterocyclyl group or a 5-6 membered heteroaryl group, which R may be substituted with one or more of the following substituents: halogen, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxy and 5-6-membered aryl.

The invention preferably selects the derivatives shown in the general formula (I) and the pharmaceutically acceptable salts or isomers thereof:

wherein R independently represents a hydrogen atom, a C1-C8 alkyl group, a C3-C6 cycloalkyl group, a phenyl group, orThe R may be substituted with one or more of the following substituents: halogen, C1-C4 alkyl, C1-C4 alkoxy, C2-C4 alkenyl.

The invention preferably relates to a compound shown in a general formula (I) and pharmaceutically acceptable salts or isomers thereof:

wherein R independently represents a hydrogen atom, a C1-C8 alkyl group, cyclopropane, phenyl, orThe R may be substituted with one or more of the following substituents: halogen, C1-C2 alkyl, C1-C2 alkoxy, C2-C4 alkenyl.

The following derivatives and pharmaceutically acceptable salts or isomers thereof are preferred in the present invention:

(3R, 4R, 5S) -4-acetylamino-5- (2-methylhydrazine-1-carboxamido) -3- (pentane-3-oxy) cyclohex-1-ene-1-carboxylic acid (I-1)

(3R, 4R, 5S) -4-acetylamino-3- (pentane-3-oxy) -5- (2-propylhydrazine-1-carboxamido) cyclohex-1-ene-1-carboxylic acid (I-2)

(3R, 4R, 5S) -4-acetylamino-5- (2-butyrylhydrazine-1-carboxamido) -3- (pentan-3-yloxy) cyclohex-1-ene-1-carboxylic acid (I-3)

(3R, 4R, 5S) -4-acetylamino-5- (2-isopentylhydrazine-1-carboxamido) -3- (pentane-3-oxy) cyclohex-1-ene-1-carboxylic acid (I-4)

(3R, 4R, 5S) -4-acetylamino-5- (2-heptahydrazide-1-carboxamido) -3- (pentane-3-oxy) cyclohex-1-ene-1-carboxylic acid (I-5)

(3R, 4R, 5S) -4-acetylamino-5- (2-benzylhydrazine-1-carboxamido) -3- (pentane-3-oxy) cyclohex-1-ene-1-carboxylic acid (I-6)

(3R, 4R, 5S) -4-acetylamino-3- (pentane-3-oxy) -5- (2-phenethylhydrazine-1-carboxamido) cyclohex-1-ene-1-carboxylic acid (I-7)

(3R, 4R, 5S) -4-acetylamino-5- (2- (2-chlorobenzyl) hydrazine-1-carboxamido) -3- (pentane-3-oxy) cyclohex-1-ene-1-carboxylic acid (I-8)

(3R, 4R, 5S) -4-acetylamino-5- (2- (3-methoxybenzyl) hydrazine-1-carboxamido) -3- (pentan-3-yloxy) cyclohex-1-ene-1-carboxylic acid (I-9)

(3R, 4R, 5S) -4-acetylamino-5- (2-cinnamoylhydrazide-1-carboxamido) -3- (pentane-3-oxy) cyclohex-1-ene-1-carboxylic acid (I-10)

(3R, 4R, 5S) -4-acetylamino-5- (2- (cyclopropylmethyl) hydrazine-1-carboxamido) -3- (pentan-3-yloxy) cyclohex-1-ene-1-carboxylic acid (I-11)

(3R, 4R, 5S) -4-acetylamino-3- (pentane-3-oxy) -5- (2- (tetrahydro-2H-pyran-4-yl) hydrazine-1-carboxamido) cyclohex-1-ene-1-carboxylic acid (I-12)

The derivatives of the invention are prepared as follows:

wherein R is as defined in the claims.

The compound is tested for the inhibitory activity of neuraminidase. Wherein the positive control drug is Oseltamivir carboxylic acid (Oseltamivir acid). The testing principle is that MUNANA (2' - (4-methylumbelliferyl) -alpha-Nacetylneuraminic acid) is a specific substrate of neuraminidase, a substance generated by neuraminidase metabolism can generate 460nm fluorescence under the excitation of 355nm light, when a tested compound acts with the neuraminidase, the binding rate of the specific substrate is changed, so that the change of fluorescence intensity is generated, the activity of the neuraminidase is reflected through the change of the fluorescence intensity, so that the inhibition rate of the compound on the neuraminidase under a specific concentration is calculated, and corresponding IC (integrated circuit) is obtained according to the inhibition rates of different concentrations₅₀The value is obtained.

The test method comprises the following steps:

add 10. mu.L of enzyme-containing solution, 70. mu.L of buffer (33mM morpholine ethanesulfonic acid, 4mM CaCl) to each well of 96-well plate₂) 10 μ L of a test compound at a given concentration was incubated at 37 ℃ for ten minutes, then 10 μ L of a fluorogenic substrate of 100 μ M was added, incubated at 37 ℃ for 30 minutes, and 150 μ L of a stop solution (83% ethanol solution of 14mM NaOH) was added to measure the fluorescence intensity, wherein the excitation wavelength was 355nm and the emission wavelength was 460 nm.

The activity test result is as follows:

name of Compound	IC50/μM	Name of Compound	IC50/μM
				I-1	0.029	I-7	2.462
I-2	0.241	I-8	0.586
				I-3	0.038	I-9	0.326
I-4	1.533	I-10	7.845
				I-5	0.575	I-11	4.111
I-6	4.345	I-12	1.207

Experimental results show that the compound has obvious neuraminidase inhibitory activity, particularly the compounds I-1, I-3, I-5, I-8 and I-9 show stronger neuraminidase inhibitory activity, and the compound has further development value.

Detailed Description

Examples 1

((3R, 4R, 5S) -4-acetamido-5- (1- (imidazole) -carbamoylamino) -3- (1-ethylpropoxy) -1-cyclohexene-1-carboxylic acid ethyl ester (II)

500mg (1.60mmol) of oseltamivir is added into a 100mL round-bottom flask, 30mL of dichloromethane is added for dissolution, 260mg (1.60mmol) of carbonyl diimidazole is added in portions under ice-water bath, and stirring is carried out. After the reaction, the organic phase was washed with saturated ammonium chloride solution and saturated sodium chloride solution, dried over anhydrous sodium sulfate, concentrated to give crude 530mg, further purified and then put into the next reaction.

EXAMPLES example 2

(3R, 4R, 5S) -4-acetylamino-5- (hydrazinecarboxamido) -3- (pentane-3-oxy) cyclohex-1-ene-1-carboxylic acid ethyl ester (III)

A100 mL round-bottomed flask was charged with 500mg (1.23mmol) of compound (3R, 4R, 5S) -4-acetylamino-5- (1- (imidazole) -carbamoylamino) -3- (1-ethylpropoxy) -1-cyclohexene-1-carboxylate (II), 1.92g of anhydrous sodium sulfate (13.52mmol) was added, and 30mL of anhydrous chloroform, 132. mu.L of hydrazine hydrate (2.71mmol) and 255. mu.L of triethylamine (1.85mmol) were sequentially added, followed by reaction at room temperature for 0.5h, followed by reaction at 35 ℃ for 12 h. After the reaction was completed, anhydrous sodium sulfate was removed by filtration, and chloroform was removed from the filtrate by evaporation under reduced pressure to obtain a crude product, which was then added with 20mL of acetonitrile and slurried to obtain 340mg of a white solid with a yield of 80.0%.

EXAMPLE 3

(3R, 4R, 5S) -4-acetylamino-5- (2-methylenehydrazine-1-carboxamido) -3- (pentane-3-oxy) cyclohex-1-ene-1-carboxylic acid ethyl ester (IV-1)

A50 mL round-bottom flask was charged with compound 200mg (0.58mmol) of ethyl (3R, 4R, 5S) -4-acetylamino-5- (hydrazinocarboxamido) -3- (pentan-3-yloxy) cyclohex-1-ene-1-carboxylate (III), followed by addition of 10mL of methanol and 25.86. mu.L of formaldehyde (0.70mmol), and stirred at room temperature for 8 h. After the reaction was completed, methanol was distilled off under reduced pressure, and purification was performed by column chromatography to obtain 201mg of a white solid with a yield of 90.0%.

EXAMPLE 4

(3R, 4R, 5S) -4-acetylamino-5- (2-methylhydrazine-1-carboxamido) -3- (pentane-3-oxy) cyclohex-1-ene-1-carboxylic acid ethyl ester (V-1)

A50 mL round-bottomed flask was charged with 200mg (0.52mmol) of ethyl (3R, 4R, 5S) -4-acetylamino-5- (2-methylenehydrazine-1-carboxamido) -3- (pentan-3-yloxy) cyclohex-1-ene-1-carboxylate (IV-1), followed by 164.30mg (2.61mmol) of sodium cyanoborohydride, 89.79. mu.L of glacial acetic acid (1.57mmol) and 10mL of methanol, stirred at room temperature for 6 hours, after completion of the reaction, saturated ammonium chloride was added thereto and quenched, methanol was distilled off under reduced pressure, followed by extraction with ethyl acetate, followed by distillation under reduced pressure of ethyl acetate and purification by column chromatography to give 165mg of a white solid in 82.9% yield.

EXAMPLE 5

(3R, 4R, 5S) -4-acetylamino-5- (2-methylhydrazine-1-carboxamido) -3- (pentane-3-oxy) cyclohex-1-ene-1-carboxylic acid (I-1)

In a 50mL round bottom flask was added compound 200mg (0.52mmol) of ethyl (3R, 4R, 5S) -4-acetylamino-5- (2-methylenehydrazine-1-carboxamido) -3- (pentan-3-oxy) cyclohex-1-ene-1-carboxylate (IV-1), followed by addition of 10mL of methanol solution and 1.04mL of 1N aqueous NaOH, supplemented with 0.96mL of deionized water to make V methanol: the reaction was stirred at room temperature with water at 5: 1. After the reaction, the pH of the reaction mixture was adjusted to 6.0 to 7.0 with ion exchange resin (Amberlite IR120, H form), filtered, evaporated under reduced pressure and purified to give 129.5mg of a white solid with a yield of 70%. 1H NMR (400MHz, CD)₃OD)δ6.81(t,J＝2.4Hz,1H),4.17–4.12(m,1H),3.96–3.91(m,2H),3.42(p,J＝5.6Hz,1H),2.84(s,3H),2.79–2.68(m,1H),2.38–2.22(m,1H),1.96(s,3H),1.58–1.46(m,4H),0.91(dt,J＝15.3,7.4Hz,6H)；MS(ESI):357.2[M+H]⁺,379.2[M+Na]⁺.

EXAMPLE 6

3R, 4R, 5S) -4-acetylamino-3- (pentane-3-oxy) -5- (2-propylhydrazine-1-carboxamido) cyclohex-1-ene-1-carboxylic acid (I-2)

The procedure is as in examples 3, 4 and 5, 200mg of (3R, 4R, 5S) -4-acetylamino-5- (hydrazinocarboxamido) -3- (pentan-3-oxy) cyclohex-1-ene-1-carboxylic acid ethyl ester (III) are used as the starting material, formaldehyde is replaced by n-propionaldehyde, and 80mg of a white solid is obtained by treatment, with a yield of 56.8%。¹H NMR(400MHz,CD₃OD)δ6.81(t,J＝2.4Hz,1H),4.21–4.09(m,1H),3.98–3.89(m,2H),3.42(p,J＝5.7Hz,1H),3.03(t,J＝7.7Hz,2H),2.80–2.67(m,1H),2.36–2.21(m,1H),1.95(s,3H),1.66(m,2H),1.58–1.46(m,4H),1.00(t,J＝7.5Hz,3H),0.90(dt,J＝15.0,7.4Hz,6H)；HRMS(ESI):407.2272[M+Na]⁺.

EXAMPLES example 7

(3R, 4R, 5S) -4-acetylamino-5- (2-butyrylhydrazine-1-carboxamido) -3- (pentan-3-yloxy) cyclohex-1-ene-1-carboxylic acid (I-3)

The procedures of example 3, example 4 and example 5 were carried out in the same manner, using 200mg of ethyl (3R, 4R, 5S) -4-acetylamino-5- (hydrazinocarboxamido) -3- (pentan-3-yloxy) cyclohex-1-ene-1-carboxylate (III) as a reaction raw material and substituting n-butyraldehyde for formaldehyde, and then conducting treatment to obtain 90.6mg of a white solid with a yield of 69.6%. 1H NMR (400MHz, CD)₃OD)δ6.81(d,J＝2.5Hz,1H),4.18–4.11(m,1H),3.98–3.90(m,2H),3.42(p,J＝5.7Hz,1H),3.10(t,J＝7.8Hz,2H),2.80–2.64(m,1H),2.35–2.22(m,1H),1.96(s,3H),1.68–1.39(m,8H),1.02–0.84(m,9H)；HRMS(ESI):399.2604[M+H]⁺,397.2432[M-H]⁺.

EXAMPLES example 8

(3R, 4R, 5S) -4-acetylamino-5- (2-isopentylhydrazine-1-carboxamido) -3- (pentane-3-oxy) cyclohex-1-ene-1-carboxylic acid (I-4)

The procedures of example 3, example 4 and example 5 were carried out, using 200mg of (3R, 4R, 5S) -4-acetylamino-5- (hydrazinocarboxamido) -3- (pentane-3-oxy) cyclohex-1-ene-1-carboxylic acid ethyl ester (III) as a reaction raw material, and isovaleraldehyde instead of formaldehyde, and then treated to obtain 106.3mg of a white solid with a yield of 75.8%. 1H NMR (400MHz, CD)₃OD)δ6.81(t,J＝2.4Hz,1H),4.14(dt,J＝6.3,3.0Hz,1H),3.97–3.91(m,2H),3.43(p,J＝5.7Hz,1H),3.19–3.03(m,2H),2.80–2.65(m,1H),2.36–2.25(m,1H),1.96(s,3H),1.74–1.63(m,1H),1.59–1.45(m,6H),1.02–0.84(m,12H)；HRMS(ESI):413.2747[M+H]⁺,435.2581[M+Na]⁺.

EXAMPLES example 9

(3R, 4R, 5S) -4-acetylamino-5- (2-heptahydrazide-1-carboxamido) -3- (pentane-3-oxy) cyclohex-1-ene-1-carboxylic acid (I-5)

The procedures of example 3, example 4 and example 5 were carried out, using 200mg of (3R, 4R, 5S) -4-acetylamino-5- (hydrazinocarboxamido) -3- (pentan-3-yloxy) cyclohex-1-ene-1-carboxylic acid ethyl ester (III) as a reaction raw material and n-heptanal in place of formaldehyde, and treating the reaction raw material to obtain 90.6mg of a white solid with a yield of 72.1%. 1H NMR (400MHz, CD)₃OD)δ6.81(t,J＝2.4Hz,1H),4.18–4.09(m,1H),3.99–3.88(m,2H),3.42(p,J＝5.7Hz,1H),3.17–3.05(m,2H),2.79–2.69(m,1H),2.36–2.24(m,1H),1.96(s,3H),1.66(p,J＝7.3Hz,2H),1.58–1.47(m,4H),1.41–1.28(m,8H),0.96–0.86(m,9H)；HRMS(ESI):463.2909[M+Na]⁺.

EXAMPLES 10

(3R, 4R, 5S) -4-acetylamino-5- (2-benzylhydrazine-1-carboxamido) -3- (pentane-3-oxy) cyclohex-1-ene-1-carboxylic acid (I-6)

The procedures of example 3, example 4 and example 5 were carried out, using 200mg of (3R, 4R, 5S) -4-acetylamino-5- (hydrazinocarboxamido) -3- (pentan-3-yloxy) cyclohex-1-ene-1-carboxylic acid ethyl ester (III) as a reaction raw material, and benzaldehyde was substituted for formaldehyde, and 130.2mg of a white solid was obtained by treatment, with a yield of 80.2%. 1H NMR (400MHz, CD)₃OD)δ7.45–6.78(m,5H),6.80(td,J＝2.6,0.9Hz,1H),4.24–4.04(m,3H),4.00–3.81(m,2H),3.42(p,J＝5.6Hz,1H),2.66(dd,J＝17.7,5.1Hz,1H),2.27–2.09(m,1H),1.95(s,3H),1.59–1.44(m,4H),0.91(dt,J＝14.8,7.4Hz,6H)；HRMS(ESI):455.2266[M+Na]⁺.

EXAMPLES example 11

(3R, 4R, 5S) -4-acetylamino-3- (pentane-3-oxy) -5- (2-phenethylhydrazine-1-carboxamido) cyclohex-1-ene-1-carboxylic acid (I-7)

The procedures of example 3, example 4 and example 5 were carried out, using 200mg of (3R, 4R, 5S) -4-acetylamino-5- (hydrazinocarboxamido) -3- (pentan-3-yloxy) cyclohex-1-ene-1-carboxylic acid ethyl ester (III) as a reaction raw material, and phenylacetaldehyde instead of formaldehyde, and then treating the reaction raw material to obtain 102.2mg of a white solid with a yield of 78.7%. 1H NMR (400MHz, CD)₃OD)δ7.36–7.29(m,2H),7.28–7.21(m,3H),6.83–6.79(m,1H),4.13(dd,J＝6.0,2.7Hz,1H),3.97–3.89(m,2H),3.42(p,J＝5.7Hz,1H),3.29–3.21(m,2H),2.92(dd,J＝9.2,6.7Hz,2H),2.73(dd,J＝17.1,4.1Hz,1H),2.31–2.20(m,1H),1.93(s,3H),1.58–1.49(m,4H),0.91(dt,J＝16.4,7.4Hz,6H)；HRMS(ESI):447.2589[M+H]⁺,469.2430[M+Na]⁺.

EXAMPLE 12

(3R, 4R, 5S) -4-acetylamino-5- (2- (2-chlorobenzyl) hydrazine-1-carboxamido) -3- (pentane-3-oxy) cyclohex-1-ene-1-carboxylic acid (I-8)

The operation is the same as that of example 3, example 4 and example 5, 200mg of (3R, 4R, 5S) -4-acetamido-5- (hydrazinoformamido) -3- (pentane-3-oxy) cyclohex-1-ene-1-carboxylic acid ethyl ester (III) is used as a reaction raw material, o-chlorobenzaldehyde is used for replacing formaldehyde, the reaction temperature is 60 ℃ when IV8 is reacted to V8, 127.35mg of white solid is obtained after treatment, and the yield is 60.2%. 1H NMR (400MHz, CD)₃OD)δ7.52–7.46(m,1H),7.46–7.39(m,1H),7.37–7.28(m,2H),6.79(td,J＝2.6,1.0Hz,1H),4.22–4.06(m,3H),3.98–3.90(m,1H),3.88–3.79(m,1H),3.42(p,J＝5.6Hz,1H),2.59(dd,J＝17.8,5.2Hz,1H),2.19–2.08(m,1H),1.95(s,3H),1.57–1.44(m,4H),0.95–0.85(m,6H)；HRMS(ESI):489.1873[M+Na]⁺.

EXAMPLES example 13

(3R, 4R, 5S) -4-acetylamino-5- (2- (3-methoxybenzyl) hydrazine-1-carboxamido) -3- (pentan-3-yloxy) cyclohex-1-ene-1-carboxylic acid (I-9)

The same procedures as in examples 3, 4 and 5 were carried out except that 200mg of ethyl (3R, 4R, 5S) -4-acetylamino-5- (hydrazinocarboxamido) -3- (pentane-3-oxy) cyclohex-1-ene-1-carboxylate (III) was used as a starting material, formaldehyde was replaced with m-methoxybenzaldehyde, and the reaction mixture was heated to 60 ℃ for reaction at IV9 to V9, and 120.6mg of a white solid was obtained by treatment in a yield of 65.2%. 1H NMR (400MHz, CD)₃OD)δ7.32(t,J＝7.8Hz,1H),7.07–6.87(m,3H),6.84–6.74(m,1H),4.19–4.04(m,3H),3.97–3.83(m,2H),3.82(s,3H),3.42(p,J＝5.6Hz,1H),2.65(dd,J＝17.7,5.2Hz,1H),2.25–2.11(m,1H),1.95(s,3H),1.58–1.45(m,4H),0.98–0.84(m,6H)；HRMS(ESI):485.2372[M+Na]⁺.

EXAMPLES example 14

(3R, 4R, 5S) -4-acetylamino-5- (2-cinnamoylhydrazide-1-carboxamido) -3- (pentane-3-oxy) cyclohex-1-ene-1-carboxylic acid (I-10)

The procedures of example 3, example 4 and example 5 were carried out in the same manner, using 200mg of (3R, 4R, 5S) -4-acetylamino-5- (hydrazinocarboxamido) -3- (pentan-3-yloxy) cyclohex-1-ene-1-carboxylic acid ethyl ester (III) as a reaction raw material and trans-cinnamaldehyde instead of formaldehyde, and then treated to give 107mg of a white solid with a yield of 71.3%. 1H NMR (600MHz, CD)₃OD)δ7.48–7.43(m,2H),7.36–7.32(m,2H),7.31–7.26(m,1H),6.80(t,J＝2.5Hz,2H),6.26(dt,J＝15.8,7.1Hz,1H),4.15–4.11(m,1H),3.98–3.89(m,2H),3.85–3.77(m,2H),3.42(p,J＝5.7Hz,1H),2.74–2.68(m,1H),2.31–2.24(m,1H),1.93(s,3H),1.55–1.48(m,4H),0.95–0.87(m,6H)；HRMS(ESI):481.2422[M+Na]⁺.

EXAMPLE 15

(3R, 4R, 5S) -4-acetylamino-5- (2- (cyclopropylmethyl) hydrazine-1-carboxamido) -3- (pentan-3-yloxy) cyclohex-1-ene-1-carboxylic acid (I-11)

The procedures of example 3, example 4 and example 5 were carried out in the same manner, using 200mg of (3R, 4R, 5S) -4-acetylamino-5- (hydrazinocarboxamido) -3- (pentan-3-yloxy) cyclohex-1-ene-1-carboxylic acid ethyl ester (III) as a reaction raw material and cyclopropanecarboxaldehyde instead of formaldehyde, and then, 97.5mg of a white solid was obtained by treatment with a yield of 74.5%. 1H NMR (400MHz, CD)₃OD)δ6.81(t,J＝2.4Hz,1H),4.22–4.09(m,1H),3.98–3.91(m,2H),3.42(p,J＝5.6Hz,1H),2.98(d,J＝7.5Hz,2H),2.79–2.63(m,1H),2.39–2.24(m,1H),1.95(s,3H),1.58–1.47(m,4H),1.04(td,J＝7.9,4.1Hz,1H),0.96–0.84(m,6H),0.73–0.62(m,2H),0.38(t,J＝5.1Hz,2H)；HRMS(ESI):397.2488[M+H]⁺,419.2266[M+Na]⁺.

EXAMPLE 16

(3R, 4R, 5S) -4-acetylamino-3- (pentane-3-oxy) -5- (2- (tetrahydro-2H-pyran-4-yl) hydrazine-1-carboxamido) cyclohex-1-ene-1-carboxylic acid (I-12)

The operation is the same as example 3, example 4 and example 5, 200mg (3R, 4R, 5S) -4-acetamido-5- (hydrazinoformamido) -3- (pentan-3-oxyl) cyclohex-1-ene-1-carboxylic acid ethyl ester (III) is used as the reaction raw material, tetrahydropyranone is used for replacing formaldehyde, and white pigment is obtained after treatment94.9mg of a colored solid, yield 65.1%. 1H NMR (400MHz, CD)₃OD)δ6.81(td,J＝2.6,1.0Hz,1H),4.16–4.10(m,1H),4.02–3.88(m,4H),3.45–3.36(m,3H),3.27–

3.13(m,1H),2.74(ddt,J＝17.6,5.0,1.4 Hz,1H),2.35–2.25(m,1H),1.96(s,3H),1.88–1.77(m,2H),1.62–1.45(m,6H),0.97–0.86(m,6H)；HRMS(ESI):449.2372[M+Na]⁺。